Thomas B Brunner1,2, Ursula Nestle3,4, Sonja Adebahr3,4, Eleni Gkika3,4, Rolf Wiehle3,4, Dimos Baltas3,4, Anca-Ligia Grosu3,4. 1. Department of Radiation Oncology, University Hospitals Freiburg, Freiburg, Deutschland. thomas.brunner@uniklinik-freiburg.de. 2. Partner Site Freiburg, German Cancer Consortium (DKTK), Heidelberg, Germany. thomas.brunner@uniklinik-freiburg.de. 3. Department of Radiation Oncology, University Hospitals Freiburg, Freiburg, Deutschland. 4. Partner Site Freiburg, German Cancer Consortium (DKTK), Heidelberg, Germany.
Abstract
OBJECTIVE: Stereotactic radiotherapy near serial organs at risk (OAR) requires special caution. A novel intensity-modulated radiotherapy (IMRT) prescription concept termed simultaneous integrated protection (SIP) for quantifiable and comparable dose prescription to targets very close to OAR is described. MATERIALS AND METHODS: An intersection volume of a planning risk volume (PRV) with the total planning target volume (PTV) defined the protection volume (PTVSIP). The remainder of the PTV represented the dominant PTV (PTVdom). Planning was performed using IMRT. Dose was prescribed to PTVdom according to ICRU in 3, 5, 8, or 12 fractions. Constraints to OARs were expressed as absolute and as equieffective doses at 2 Gy (EQD2). Dose to the gross risk volume of an OAR was to respect constraints. Violation of constraints to OAR triggered a planning iteration at increased fractionation. Dose to PTVSIP was required to be as high as possible within the constraints to avoid local relapse. RESULTS: SIP was applied in 6 patients with OAR being large airways (n = 2) or bowel (n = 4) in 3, 5, 8, and 12 fractions in 1, 3, 1, and 1 patients, respectively. PTVs were 14.5-84.9 ml and PTVSIP 1.8-3.9 ml (2.9-13.4 % of PTV). Safety of the plans was analyzed from the absolute dose-volume histogram (dose to ml). The steepness of dose fall-off could be determined by comparing the dose constraints to the PRVs with those to the OARs (Wilcoxon test p = 0.001). Constraints were respected for the corresponding OARs. All patients had local control at a median 9 month follow-up and toxicity was low. CONCLUSION: SIP results in a median dose of ≥100 % to PTV, to achieve high local control and low toxicity. Longer follow-up is required to verify results and a prospective clinical trial is currently testing this new approach in chest and abdomen stereotactic body radiotherapy.
OBJECTIVE: Stereotactic radiotherapy near serial organs at risk (OAR) requires special caution. A novel intensity-modulated radiotherapy (IMRT) prescription concept termed simultaneous integrated protection (SIP) for quantifiable and comparable dose prescription to targets very close to OAR is described. MATERIALS AND METHODS: An intersection volume of a planning risk volume (PRV) with the total planning target volume (PTV) defined the protection volume (PTVSIP). The remainder of the PTV represented the dominant PTV (PTVdom). Planning was performed using IMRT. Dose was prescribed to PTVdom according to ICRU in 3, 5, 8, or 12 fractions. Constraints to OARs were expressed as absolute and as equieffective doses at 2 Gy (EQD2). Dose to the gross risk volume of an OAR was to respect constraints. Violation of constraints to OAR triggered a planning iteration at increased fractionation. Dose to PTVSIP was required to be as high as possible within the constraints to avoid local relapse. RESULTS: SIP was applied in 6 patients with OAR being large airways (n = 2) or bowel (n = 4) in 3, 5, 8, and 12 fractions in 1, 3, 1, and 1 patients, respectively. PTVs were 14.5-84.9 ml and PTVSIP 1.8-3.9 ml (2.9-13.4 % of PTV). Safety of the plans was analyzed from the absolute dose-volume histogram (dose to ml). The steepness of dose fall-off could be determined by comparing the dose constraints to the PRVs with those to the OARs (Wilcoxon test p = 0.001). Constraints were respected for the corresponding OARs. All patients had local control at a median 9 month follow-up and toxicity was low. CONCLUSION: SIP results in a median dose of ≥100 % to PTV, to achieve high local control and low toxicity. Longer follow-up is required to verify results and a prospective clinical trial is currently testing this new approach in chest and abdomen stereotactic body radiotherapy.
Entities:
Keywords:
Efficacy; Intensity-modulated radiotherapy; Organs at risk; Stereotactic body radiation therapy; Toxicity
Authors: Morten Hoyer; Henrik Roed; Lisa Sengelov; Anders Traberg; Lars Ohlhuis; Jorgen Pedersen; Hanne Nellemann; Anne Kiil Berthelsen; Frey Eberholst; Svend Aage Engelholm; Hans von der Maase Journal: Radiother Oncol Date: 2005-07 Impact factor: 6.280
Authors: Florian Sterzing; Thomas B Brunner; Iris Ernst; Wolfgang W Baus; Burkhard Greve; Klaus Herfarth; Matthias Guckenberger Journal: Strahlenther Onkol Date: 2014-08-05 Impact factor: 3.621
Authors: Angela van Baardwijk; Wolfgang A Tomé; Wouter van Elmpt; Søren M Bentzen; Bart Reymen; Rinus Wanders; Ruud Houben; Michel Ollers; Philippe Lambin; Dirk De Ruysscher Journal: Radiother Oncol Date: 2012-10-12 Impact factor: 6.280
Authors: Morten Busk; Michael R Horsman; Steen Jakobsen; Kim V Hansen; Johan Bussink; Albert van der Kogel; Jens Overgaard Journal: Radiother Oncol Date: 2009-09-02 Impact factor: 6.280
Authors: M Guckenberger; N Andratschke; H Alheit; R Holy; C Moustakis; U Nestle; O Sauer Journal: Strahlenther Onkol Date: 2013-09-21 Impact factor: 3.621
Authors: Lotte Wilke; Nicolaus Andratschke; Oliver Blanck; Thomas B Brunner; Stephanie E Combs; Anca-Ligia Grosu; Christos Moustakis; Daniela Schmitt; Wolfgang W Baus; Matthias Guckenberger Journal: Strahlenther Onkol Date: 2019-01-16 Impact factor: 3.621
Authors: E Gkika; S Adebahr; S Kirste; T Schimek-Jasch; R Wiehle; R Claus; U Wittel; U Nestle; D Baltas; A L Grosu; T B Brunner Journal: Strahlenther Onkol Date: 2017-01-30 Impact factor: 3.621
Authors: Eleni Gkika; Dominik Bettinger; Leo Krafft; Michael Schultheiss; Hannes Philipp Neeff; Lars Maruschke; Michaela Schulenburg; Sonja Adebahr; Simon Kirste; Ursula Nestle; Robert Thimme; Anca-Ligia Grosu; Thomas Baptist Brunner Journal: Strahlenther Onkol Date: 2018-01-10 Impact factor: 3.621
Authors: Eleni Gkika; Iosif Strouthos; Simon Kirste; Sonja Adebahr; Michael Schultheiss; Dominik Bettinger; Ralph Fritsch; Volker Brass; Lars Maruschke; Hannes Philipp Neeff; Sven Arke Lang; Ursula Nestle; Anca-Ligia Grosu; Thomas Baptist Brunner Journal: Strahlenther Onkol Date: 2018-10-23 Impact factor: 3.621
Authors: Sergiu Scobioala; Ross Parfitt; Peter Matulat; Christopher Kittel; Fatemeh Ebrahimi; Heidi Wolters; Antoinette Am Zehnhoff-Dinnesen; Hans Theodor Eich Journal: Strahlenther Onkol Date: 2017-09-08 Impact factor: 3.621